Aspirin in secondary prevention of recurrent venous thromboembolism

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 3, 2015, Pages 392-394

  Boonyawat, Kochawan ^a   Crowther, Mark A ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PLACEBO; WARFARIN;

ARTICLE; BLEEDING; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LUNG EMBOLISM; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ASPIRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; VENOUS THROMBOEMBOLISM;

EID: 84925461409     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1196-4     Document Type: Article

References (24)

1. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P et al (2012) Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e637S–e668S
2. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308(6923):235–246
3. Pulmonary Embolism Prevention (PEP) trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355(9212):1295–1302
4. Undas A, Brummel-Ziedins K, Mann KG (2014) Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thrombo Haemost 12(11):1776–1787
5. Steele P (1980) Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet 2(8208–8209):1328–1329
6. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M et al (2012) Aspirin for preventing the recurrence of venous thromboembolism. New Engl J Med 366(21):1959–1967
7. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P et al (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. New Engl J Med 367(21):1979–1987
8. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R et al (2014) Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 130(13):1062–1071
9. Milan M, Noventa F, Ghirarduzzi A, Pengo V, Vedovetto V, Filippi L et al (2012) Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. J Thrombo Haemost 10(10):2205–2206
10. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, The Duration of Anticoagulation Trial Study Group et al (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New Engl J Med 336(6):393–398
11. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New Engl J Med 340(12):901–907
12. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Warfarin Optimal Duration Italian Trial Investigators et al (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. New Engl J Med 345(3):165–169
13. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M et al (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139(1):19–25
14. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P (2007) The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 147(11):766–774
15. Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ et al (2008) Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 6(7):1105–1112
16. Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA et al (2014) The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation 130(18):1636–1661
17. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D et al (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150(9):577–585
18. Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C et al (2008) Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 112(3):511–515
19. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T et al (2008) Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 149(7):481–490 W94
20. Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S et al (2010) Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115(3):481–488
21. Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 363(26):2499–2510
22. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Apixaban for extended treatment of venous thromboembolism. New Engl J Med 368(8):699–708
23. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New Engl J Med 368(8):709–718
24. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S